IN2012DN00311A - - Google Patents

Info

Publication number
IN2012DN00311A
IN2012DN00311A IN311DEN2012A IN2012DN00311A IN 2012DN00311 A IN2012DN00311 A IN 2012DN00311A IN 311DEN2012 A IN311DEN2012 A IN 311DEN2012A IN 2012DN00311 A IN2012DN00311 A IN 2012DN00311A
Authority
IN
India
Prior art keywords
nanoparticles
solid phase
composition
solid
phase
Prior art date
Application number
Other languages
English (en)
Inventor
Alexander Vol
Orna Gribova
Original Assignee
Oshadi Drug Administration Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oshadi Drug Administration Ltd filed Critical Oshadi Drug Administration Ltd
Publication of IN2012DN00311A publication Critical patent/IN2012DN00311A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN311DEN2012 2009-07-09 2010-07-08 IN2012DN00311A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22410009P 2009-07-09 2009-07-09
PCT/IL2010/000551 WO2011004376A1 (fr) 2009-07-09 2010-07-08 Compositions de support matriciel, procédés et utilisations

Publications (1)

Publication Number Publication Date
IN2012DN00311A true IN2012DN00311A (fr) 2015-05-08

Family

ID=43428853

Family Applications (1)

Application Number Title Priority Date Filing Date
IN311DEN2012 IN2012DN00311A (fr) 2009-07-09 2010-07-08

Country Status (14)

Country Link
US (2) US9060932B2 (fr)
EP (1) EP2451442A4 (fr)
CN (2) CN102099011B (fr)
AU (1) AU2010269815B2 (fr)
BR (1) BR112012000379A2 (fr)
CA (1) CA2767342C (fr)
IL (1) IL249939A0 (fr)
IN (1) IN2012DN00311A (fr)
MX (1) MX340134B (fr)
NZ (1) NZ597326A (fr)
RU (1) RU2528895C2 (fr)
SG (2) SG10201403918RA (fr)
WO (1) WO2011004376A1 (fr)
ZA (1) ZA201109321B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL188647A0 (en) 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
IN2012DN00311A (fr) * 2009-07-09 2015-05-08 Oshadi Drug Administration Ltd
RU2532032C1 (ru) * 2013-03-21 2014-10-27 Сергей Алексеевич Успенский Твердофазный способ получения водорастворимого биоактивного нанокомпозита на основе модифицированной меланином соли гиалуроновой кислоты и наночастиц золота
RU2544166C2 (ru) * 2013-05-14 2015-03-10 Александр Александрович Кролевец Способ получения микрокапсул оксида цинка
US9168211B2 (en) * 2014-03-28 2015-10-27 Johnson & Johnson Consumer Inc. Method of making an anhydrous, pigmented composition
US10398732B2 (en) 2016-10-13 2019-09-03 Marshall University Research Corporation Compositions and methods for treating striated muscle injury, treating striated muscle atrophy and/or for promoting striated muscle growth
CN108451787B (zh) * 2018-05-23 2020-01-07 上海格兰化妆品有限公司 一种包埋维生素a醇的纳米脂质载体及其制备方法
US20200383932A1 (en) * 2019-06-05 2020-12-10 The Florida International University Board Of Trustees Biotherapy for viral infections using biopolymer based micro/nanogels
US12263252B2 (en) 2019-06-05 2025-04-01 The Florida International University Board Of Trustees Biotherapy for viral infections using biopolymer based micro/nanogels
CN115389659B (zh) * 2022-08-23 2024-07-16 浙江中医药大学 一种细胞膜键合磁性碳球复合材料及其制备方法和应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3252859A (en) 1962-10-24 1966-05-24 Masti Kure Company Inc Colloidal silica-oil composition and method of using same
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
ES2027518A6 (es) 1990-12-18 1992-06-01 Andromaco Lab Procedimiento para la preparacion de nuevas asociaciones no covalentes polisacarido-proteina con actividad farmacologica.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5260002A (en) 1991-12-23 1993-11-09 Vanderbilt University Method and apparatus for producing uniform polymeric spheres
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US20040018236A1 (en) 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
ES2093562B1 (es) 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6071535A (en) 1996-01-31 2000-06-06 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US5874105A (en) 1996-01-31 1999-02-23 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US6322765B1 (en) 1996-02-15 2001-11-27 Wacker-Chemie Gmbh Process for preparing silicon dioxide
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
FR2767718B1 (fr) * 1997-08-28 1999-10-22 Oreal Emulsion eau-dans-huile comprenant de la silice pyrogenee et un alkylether de polysaccharide
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
TR199901008T1 (xx) 1997-09-09 2000-02-21 Select Release, L.C. Kaplanm�� partik�ller, yap�m� ve kullan�m y�ntemleri.
FR2773804B1 (fr) 1998-01-19 2000-02-18 Sanofi Sa Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant
US6656922B2 (en) 1998-05-28 2003-12-02 Mediplex Corporation, Korea Oral delivery of macromolecules
MX339071B (es) 1999-03-31 2016-05-09 Janssen Pharmaceutica Nv Almidon pregelatinizado en una formulacion de liberacion controlada.
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US7195780B2 (en) 2002-10-21 2007-03-27 University Of Florida Nanoparticle delivery system
DE10001172A1 (de) 2000-01-13 2001-07-26 Max Planck Gesellschaft Templatieren von Feststoffpartikeln mit Polymermultischichten
JP4631119B2 (ja) 2000-01-28 2011-02-16 Ｊｓｒ株式会社 疎水化コロイダルシリカの製造方法
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US6548264B1 (en) 2000-05-17 2003-04-15 University Of Florida Coated nanoparticles
NZ523017A (en) 2000-06-29 2004-10-29 Emisphere Tech Inc Compounds and compositions for delivering active agents and preparation method thereof
DE50012404D1 (de) * 2000-08-11 2006-05-11 Lohmann Animal Health Gmbh W/o Emulsion Adjuvanszuzammensetzungen für Impstoffen
WO2002032398A2 (fr) 2000-10-16 2002-04-25 Massachusetts Institute Of Technology Particules de lipide-proteine-sucre pour l'apport de medicaments
FR2819720B1 (fr) 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
US6698247B2 (en) 2001-05-04 2004-03-02 Corning Incorporated Method and feedstock for making silica by flame combustion
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
WO2003055469A1 (fr) 2001-12-21 2003-07-10 Celator Technologies Inc. Vecteur ameliore a base de polymere et de lipide
US20030235619A1 (en) 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US6824790B2 (en) 2002-01-09 2004-11-30 Enzrel Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
WO2003066859A2 (fr) 2002-02-07 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sequences d'acides amines facilitant la penetration a travers une barriere biologique
US7244498B2 (en) 2002-06-12 2007-07-17 Tda Research, Inc. Nanoparticles modified with multiple organic acids
US7090868B2 (en) 2002-09-13 2006-08-15 University Of Florida Materials and methods for drug delivery and uptake
US7384914B2 (en) 2003-01-06 2008-06-10 Emisphere Technologies, Inc. Night-time oral insulin therapy
US20040242729A1 (en) * 2003-05-30 2004-12-02 3M Innovative Properties Company Stabilized particle dispersions containing surface-modified inorganic nanoparticles
AU2004317954A1 (en) 2003-09-17 2005-10-13 Chiasma, Inc. Compositions capable of facilitating penetration across a biological barrier
JP2007509981A (ja) 2003-10-31 2007-04-19 テバ ファーマシューティカル インダストリーズ リミティド 薬物デリバリー用ナノ粒子
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
CA2563533C (fr) 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capables de faciliter la penetration a travers une barriere biologique
US7288134B2 (en) 2004-09-10 2007-10-30 International Business Machines Corporation Dumbbell-like nanoparticles and a process of forming the same
US7282194B2 (en) 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
WO2006044660A2 (fr) 2004-10-14 2006-04-27 Vanderbilt University Nanoparticules lipidiques solides fonctionnalisees et procedes de fabrication et d'utilisation associes
WO2006062506A1 (fr) 2004-12-03 2006-06-15 Enzrel, Inc. Administration de composes antioxydants ou anti-inflammatoires au moyen d'un medicament liposomal enrobe de chitosane
JP4920685B2 (ja) 2005-08-09 2012-04-18 ユニヴァーシティ・オヴ・サンダーランド 質量分析を使用する指紋分析
ES2761937T3 (es) * 2005-10-24 2020-05-21 Magsense Life Sciences Inc Método para preparar micropartículas recubiertas con polímero
US20070104778A1 (en) 2005-11-07 2007-05-10 Hongxia Zeng Controlled-release emulsion compositions
WO2008048288A2 (fr) 2005-11-09 2008-04-24 Montana State University Nouvelles nanoparticules et leur utilisation
US20070134332A1 (en) 2005-11-21 2007-06-14 Medivas, Llc Polymer particles for delivery of macromolecules and methods of use
US20070184076A1 (en) 2006-02-07 2007-08-09 Unger Evan C Liquid-filled nanodroplets for anti-cancer therapy
WO2007121256A2 (fr) 2006-04-12 2007-10-25 Biodel, Inc. Formulations de combinaison d'insuline à action prolongée et à action rapide
IL188647A0 (en) 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
AU2008346276B2 (en) 2008-01-11 2013-05-16 Pii Limited Pipeline inspection apparatus and method using two different ultrasound wavemodes
IN2012DN00311A (fr) * 2009-07-09 2015-05-08 Oshadi Drug Administration Ltd

Also Published As

Publication number Publication date
NZ597326A (en) 2013-05-31
MX340134B (es) 2016-06-28
IL249939A0 (en) 2017-03-30
SG177536A1 (en) 2012-03-29
CN105997864A (zh) 2016-10-12
EP2451442A1 (fr) 2012-05-16
US9504648B2 (en) 2016-11-29
US9060932B2 (en) 2015-06-23
RU2012104554A (ru) 2013-08-20
BR112012000379A2 (pt) 2016-03-29
CA2767342C (fr) 2018-05-01
CA2767342A1 (fr) 2011-01-13
CN102099011A (zh) 2011-06-15
US20120100216A1 (en) 2012-04-26
ZA201109321B (en) 2013-02-27
AU2010269815B2 (en) 2015-10-15
RU2528895C2 (ru) 2014-09-20
CN102099011B (zh) 2016-06-01
SG10201403918RA (en) 2014-10-30
MX2012000376A (es) 2012-02-28
AU2010269815A1 (en) 2012-01-19
US20150245993A1 (en) 2015-09-03
WO2011004376A1 (fr) 2011-01-13
EP2451442A4 (fr) 2014-02-12

Similar Documents

Publication Publication Date Title
MX2012000376A (es) Composiciones portadoras de matriz, metodos y usos.
WO2009061607A3 (fr) Matières non miscibles à l'eau en tant que véhicules pour l'administration d'un médicament
EP2152442A4 (fr) Système de recirculation de fluide s'utilisant dans un système de production de particules en phase vapeur
WO2008131265A3 (fr) Seringue ergonomique
WO2010140007A9 (fr) Forme pharmaceutique
EP2195377B8 (fr) Réducteurs de traînée hybrides à teneur élevée en polymère
WO2011060353A3 (fr) Points quantiques noyau-enveloppe à désadaptation de réseau
WO2009111367A3 (fr) Dispositif d'extension de base de siège actionné par matière active
CA121629S (en) Bottle
WO2009097508A3 (fr) Procédés et compositions pour la cicatrisation
HK1187637A1 (en) Nanowire ink compositions and printing of same
MX348491B (es) Tableta a prueba de manipulacion que proporciona liberacion inmediata de fármaco.
WO2010080764A3 (fr) Système d'apport de doses pharmaceutiques
WO2011051971A3 (fr) Dispersion solide de rifaximine
SI2230932T1 (sl) Oplaščeni farmacevtski ali nutracevtski pripravek s povečanim sproščanjem aktivne učinkovine v črevesu
IL217208A (en) History of cryptophycin, critophycin conjugates, processes for their preparation, and their use as anticancer agents
EP2195909A4 (fr) Système de palier hybride de retombée
MX2010000151A (es) Revestimientos a base de agua de curacion en condiciones ambientales para superficies escribibles-borrables.
AU329495S (en) Sprayer
MX336324B (es) Organometalovidrio hibrido polimerico.
WO2010145849A3 (fr) Systèmes de délivrance de médicaments
EP2249817B8 (fr) Vecteurs de nanoparticules pour l administration de médicaments et procédé pour leur production
AR114086A2 (es) Polvos para reconstitución
EP2462938A4 (fr) Polymère anionique, complexe polyions utilisant un polymère anionique, composite de polymère ternaire, et composition pharmaceutique
EP2245091A4 (fr) Dispersion de nanoparticules, compositions la contenant et articles obtenus à partir de celles-ci